Strategic Partners

Partnerships to be proud of.

We have forged strategic partnerships with leading companies around the world. Our operating model allows us to leverage our strengths globally, while enjoying local market expertise, whether it is a US state’s medical marijuana program or one of many regulated international markets.  We can act with unmatched speed and agility in reaction to evolving market conditions to reach our goal of improving the lives of as many people around the world as we can.   

Neuraxpharm is a leading European specialty pharmaceutical company focused on the treatment of central nervous system disorders (CNS) with a direct presence in Germany, Spain, France, Italy, Czech Republic, Poland, Austria, Switzerland, Slovakia, United Kingdom, Hungary and Portugal. Backed by funds advised by Apax Partners, Neuraxpharm has a unique understanding of the CNS market built over 35 years.

With its focus on CNS, Neuraxpharm develops and commercializes value added medicines, standard generics and Consumer Healthcare products, e.g. probiotics and other nutraceuticals, and is continuously striving to offer a wide range of effective, high quality and affordable CNS treatment options in Europe.

Present with its products in more than 50 countries, Neuraxpharm also manufactures pharmaceutical products and active pharmaceutical ingredients in its own manufacturing sites in Spain, Lesvi and Inke.

Rafa is a pharmaceutical company in Israel that markets, manufactures and distributes prescription (Rx) and over-the-counter (OTC) medicines, mainly proprietary formulations, as well as generic formulations, and consumer health products.

With a history of over 80 years, Rafa is a trusted partner of some of the leading pharmaceutical companies, such as Mundipharma, Napp, Purdue, Galderma, Takeda, AstraZeneca, Dr. Falk Pharma, Helsinn and more. All companies operate under safety, development and manufacturing global standards.

EUMCA is the voice for ethical European manufacturers and suppliers of pharmaceutical grade cannabis. EUMCA also represent the interests of pharmaceutical and healthcare organisations who have an interest in establishing their presence in this fast-evolving industry sector. Their primary goal is to establish and promote a standardised, ethical market for medicinal cannabis throughout the whole of Europe.

Ultra Health is New Mexico’s #1 Cannabis Company and the largest vertically integrated medical cannabis provider in the United States. The provider currently operates 17 dispensary locations statewide, with another 13 stores slated to open by year end. Ultra Health provides unparalleled medical cannabis care by producing accurately dosed, smokeless cannabis products such as sublingual tablets, oils, pastilles, suppositories and more through its partnership with Israeli pharmaceutical group Panaxia. Ultra Health has been on the forefront of patient-rights issues and continues to fight for adequate supply and rural access in the New Mexico medical cannabis market.

Ocean Grown Ventures (OGV) ,Founded in 2017, is a California based holding & operating company that develops products and partnerships focused on bringing the highest quality solutions and scientific innovations in medical cannabis to the United States. Ocean Grown Venture’s first strategic partnership was with Panaxia Pharmaceutical Industries Together in late 2019 they introduced to market Tikva by Panaxia.

Tikva by Panaxia Pharmaceuticals is an Ocean Grown Ventures family brand. The line of full-spectrum hemp CBD wellness products includes oils, tablets, and creams at varying concentrations. Tikva’s products are manufactured in Good Manufacturing Practice (GMP) compliant, stabilized cleanroom environments under stringent guidelines and regulations typically required of FDA regulated pharmaceutical companies. Each product is guaranteed to have and do exactly what it says on the bottle, and Panaxia has the clinical studies and data to prove it.

MPX Bioceutical Corporation (formerly BCC) aims to become one of the largest players in the adult cannabis industry. MPX Bioceutical Corporation owns subsidiaries in the United States, and provides management, staff, advisory, financial, procurement and administrative services to two ventures in Arizona. MPX Bioceutical Corporation provides the support necessary for its partners to successfully market their therapeutic cannabis partners. Panaxia and MPX Bioceutical Corporation announced their partnership in Summer 2017. Under the agreement, Panaxia will provide smokeless, pharma-grade products that are not easily obtainable in the United States.

Salus Biopharma’s mission is to provide medical cannabis products developed with cutting edge technologies to the highest available pharmacy standards. The Company manufactures and markets pharmacy grade cannabis based products developed with partner Panaxia Industries Inc. All products  are manufactured to GMP standards and provide accurate, specific and reproducible dosing. Salus Biopharma is a wholly-owned subsidiary of MPX Bioceutical Corporation.

Nabis Holdings Inc. is a Canadian investment company focused on investing in high quality cash flowing and strategic assets across multiple aspects of the cannabis sector primarily in U.S limited license states with a roadmap to expand globally.

Seach Medical Cannabis Group is a family based company, part of agriculture farm based in Hasharon area in Israel which has been active in the agriculture field for more than 70 years.
Seach is a pioneer player in the medical Cannabis field in Israel and worldwide. For more than a decade, Seach has been growing and supplying medical Cannabis to thousands of patients in Israel, to the Israeli ministry of health and to research institutions.

Seach owns a 14,000 SqM medical Cannabis farm equipped with fully automated greenhouse and research facilities. Seach is currently supplying 13 unique strains of the plant, designated for treatments of various medical indications. In addition, Seach is constantly involved in breeding and development of additional strains and technologies in the medical Cannabis field.

Cann10 is an active member of the medical cannabis industry. With offices and activities in more than 10 countries, Cann10 is also licensed in Israel to produce and will trade in medical cannabis.
Cann 10 is involved in growing, producing, marketers and we help investors make the right decisions. 
Cann10 manage, invests and develops startups involved in the medical cannabis ecosystem through the Cann10XL accelerator. Cann10 will provide high-quality cannabis, cannabis derivatives, and other products and services to medical dispensaries and directly to patients, as well as to pharmaceutical companies and for scientific research, around the world with the Cann10 brand “Cannareet”.

Better has over 15 years of experience and knowledge in production of cannabis strains for medical usage. Specializing in organic growing techniques and developing unique products for different delivery system, Better has become one of the first and largest producers of Medical Grade Cannabis in Israel and is expanding to the global market to create a Better world.ett

International Medical Cannabis (“IMC”) is a leading medical cannabis provider. Since 2010, the company has offered a full spectrum of government-licensed cannabis products, from generic to GMP-certified and pharmaceutical-grade, for both wholesale and retail clients. IMC is an industrial innovator, constantly moving forward in the rapidly developing medical cannabis market and closely collaborating with research institutions and start-up companies.

Canndoc has been pioneering Pharma-Grade cannabis for more than 12 years. Over the years, Canndoc provided more than 750,000 doses to 20,000 patients, establishing its position as a venerable player in this global industry, demonstrating significant expertise across the entire value chain from research, cultivation, and processing, to product development and advanced GMP clinical trials pipeline initiation.

Driven by the mission of meeting patients’ needs and improving their quality of life, Canndoc holds product efficacy to be of paramount importance, delivering Good Manufacturing Practice (GMP) pharma-grade cannabis solutions to achieve better patient health and treatment outcomes.